LP
SMMT icon

LMR Partners’s Summit Therapeutics SMMT Stock Holding History

LMR Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4M Buy
600,400
+176,000
+41% +$2.85M 0.03% 374
2025
Q4 		$7.42M Buy
424,400
+15,300
+4% +$288K 0.01% 478
2025
Q3 		$8.45M Buy
409,100
+225,300
+123% +$5.46M 0.04% 376
2025
Q2 		$3.91M Buy
183,800
+47,000
+34% +$1.07M 0.03% 514
2025
Q1 		$2.64M Buy
136,800
+15,000
+12% +$301K 0.02% 596
2024
Q4 		$2.17M Buy
121,800
+21,800
+22% +$423K 0.02% 578
2024
Q3 		$2.19M Buy
100,000
+50,000
+100% +$699K 0.02% 582
2024
Q2 		$390K Buy
+50,000
New +$270K ﹤0.01% 800

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

LMR Partners's SMMT Position: Q1 2026 in Review

LMR Partners reduced its Summit Therapeutics (SMMT) stake by 55% in Q1 2026, selling an estimated $664K and leaving 34,122 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #1057.

LMR Partners first reported a position in SMMT in Q1 2021 and has held it in 4 quarters since. The position peaked at $1.32M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • LMR Partners held 34,122 shares of Summit Therapeutics worth $647K as of Q1 2026.
  • LMR Partners sold 41,078 Summit Therapeutics shares in Q1 2026, an estimated $664K.
  • Summit Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1057 holding.
  • LMR Partners first reported a position in Summit Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • LMR Partners's Summit Therapeutics position peaked at $1.32M in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.